Prothena Corporation PLC (PRTA) Actualités

Form 8-K - Current report

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023;...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Updates on PRX012 and PRX123 for treatment of Alzheimer’s disease, and on birtamimab for treatment of AL amyloidosis Remain on track with...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report